Acute and chronic systemic and pulmonary hemodynamic effects of angiotensin converting enzyme inhibition with captopril in hypertensive patients

This publication has 24 references indexed in Scilit:

• Oral Angiotensin-Converting Enzyme Inhibitor in Long-Term Treatment of Hypertensive Patients
  Annals of Internal Medicine, 1979
• Systemic and pulmonary hemodynamic effects of saralasin infusion in hypertension: Predictability of plasma renin status from hemodynamic changes
  The American Journal of Cardiology, 1978
• Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients
  Progress in Cardiovascular Diseases, 1978
• EFFECTS OF 1-SAR-8-ALA-ANGIOTENSIN II ON SYSTEMIC AND PULMONARY HAEMODYNAMICS IN HYPERTENSIVE PATIENTS
  Clinical and Experimental Pharmacology and Physiology, 1978
• Effects of angiotensin antagonism at rest and during exercise in sodium-deplete man
  Journal of Applied Physiology, 1978
• Effects of the angiotensin II antagonist 1-sar-8-ala-angiotensin II in hypertension in man
  European Journal of Clinical Investigation, 1977
• Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive Agents
  Science, 1977
• Usefulness and limitations of saralasin, a partial competitive agonist of angiotensin II, for evaluating the renin and sodium factors in hypertensive patients
  The American Journal of Medicine, 1976
• Use of an Angiotensin II Antagonist (Saralasin) in the Recognition of “Angiotensinogenic” Hypertension
  New England Journal of Medicine, 1975
• A Specific Competitive Antagonist of the Vascular Action of Angiotensin II
  Circulation Research, 1971